50 results
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
2 Apr 24
Bio-Path Holdings Provides 2024 Clinical and Operational Update
4:10pm
package to accompany prexigebersen treatment and expects to evaluate prexigebersen for the treatment of obesity. In addition, one further drug candidate … in an Investigational New Drug (IND) application.
Development of Molecular Biomarkers – Bio-Path is developing a molecular biomarker package to accompany
8-K
EX-10.1
ysbi bc4v5pf8n
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
424B3
fl6ubtpp 0h
7 Aug 23
Prospectus supplement
7:21am
8-K
EX-99.2
kcs1ufv5ymcnz6sn7 4k
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
8-K
EX-99.1
igbt85
5 Apr 21
Regulation FD Disclosure
4:54pm
8-K
EX-99.1
89o7ge
17 Feb 21
Placement Agency Agreement
5:11pm